

1 Facing the Omicron variant – How well do vaccines protect against mild and severe 2 COVID-19? Third interim analysis of a living systematic review

3 **Wiebe Külper-Schiek^{1†}, Vanessa Piechotta^{1†}, Antonia Pilic¹, Madeleine Batke¹, Léa-
4 Sophie Drevet¹, Brogan Geurts², Judith Koch¹, Stefan Köppe¹, Marina Treskova^{1,3},
5 Sabine Vygen-Bonnet¹, Maria Waize¹, Ole Wichmann¹, Thomas Harder¹**

6 ¹ Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

7 ² Centre for International Health Protection, Robert Koch Institute, Berlin, Germany

8 ³ Institute of Global Health, Heidelberg University Hospital, Heidelberg, Germany

9 † these authors have contributed equally to this work and share first authorship

10 **Keywords: SARS-CoV-2₁; systematic review₂; vaccine effectiveness₃; vaccination₄;
11 COVID-19₅; Omicron variant₆; variant of concern₇.**

12 **Abstract**

13 **Background:**

14 The SARS-CoV-2 Omicron variant is currently the dominant variant globally. This 3rd interim
15 analysis of a living systematic review summarizes evidence on COVID-19 vaccine
16 effectiveness (VE) and duration of protection against Omicron.

17 **Methods:**

18 We systematically searched the COVID-19 literature for controlled studies evaluating the
19 effectiveness of COVID-19 vaccines approved in the European Union up to 14/01/2022,
20 complemented by hand-searches of websites and metasearch engines up to 11/02/2022. We
21 considered the following comparisons: full primary immunization vs. no vaccination; booster
22 immunization vs. no vaccination; booster vs. primary immunization. VE against any confirmed
23 SARS-CoV-2 infection, symptomatic, and severe COVID-19 (i.e. COVID-19-related
24 hospitalization, ICU-admission, or death) was indicated providing estimate ranges. Meta-
25 analysis was not performed due to high study heterogeneity. Risk of bias was assessed with
26 ROBINS-I, certainty of evidence evaluated using GRADE.

27 **Results:**

28 We identified 26 studies, including 430 to 2.2 million participants.

29 VE against any confirmed SARS-CoV-2 infection compared to no vaccination ranged between
30 0-62% after full primary immunization, and between 34-66% after a booster dose. VE-range
31 for booster vs. primary immunization was 34-54.6%.

32 Against symptomatic COVID-19, VE ranged between 6-76% after full primary immunization,
33 and between 19-73.9% after booster immunization, if compared to no vaccination. When
34 comparing booster vs. primary immunization VE ranged between 56-69%.

35 VE against severe COVID-19 compared to no vaccination ranged between 3-84% after full
36 primary immunization, and between 12-100% after a booster dose. One study compared booster
37 vs. primary immunization (VE 100%, 95% CI 71.4-100).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

38 VE was characterized by a moderate to strong decline within three to six months for SARS-
39 CoV-2 infections and symptomatic COVID-19. Against severe COVID-19 protection remained
40 robust at least for up to six months. Waning immunity was more profound after primary than
41 booster immunization.

42 Risk of bias was moderate to critical across studies and outcomes. GRADE-certainty was very
43 low for all outcomes.

44 **Author's conclusions:**

45 Under the Omicron variant, effectiveness of EU-licensed COVID-19 vaccines in preventing
46 any SARS-CoV-2 infection or mild disease is low and only short-lasting after primary
47 immunization, but can be improved by booster vaccination. VE against severe COVID-19
48 remains high and is long-lasting, especially after receiving the booster vaccination.

49

50 1 Introduction

51 The Omicron variant of SARS-CoV-2 (Phylogenetic Assignment of Named Global Outbreak
52 (Pango) lineage designation B.1.1.529) was first detected in South-Africa in November 2021.
53 Since then, the variant spread rapidly across countries and has largely replaced all other variants
54 globally (>99,8% of all sequences submitted to the Global Initiative on Sharing All Influenza
55 Data (GISAID) were Omicron in week 5 of 2022) (1). Evidence suggests that the Omicron
56 variant has a growth rate advantage compared to the previously dominant Delta variant, leading
57 to its overtake as the dominant variant globally, while the Delta variant now only represents
58 0.1% of collected samples (1).

59 High rates of asymptomatic infection and symptomatic COVID-19 disease among people
60 previously infected with SARS-CoV-2 or fully vaccinated with a COVID-19 vaccine raise
61 concerns that the currently available vaccines are less or no-longer effective against the
62 Omicron variant. To summarize the existing evidence on the effectiveness and the duration of
63 protection conferred by COVID-19 vaccines licensed in the European Union (EU) with respect
64 to the Omicron variant, and compare it to the Delta variant, we synthesized the evidence within
65 an ongoing living systematic review (LSR), conducted by Robert Koch Institute (RKI) in
66 collaboration with the National Immunisation Technical Advisory Groups (NITAGs) network
67 coordinated by the European Centre for Disease Prevention and Control (ECDC) (2).

68

69 2 Methods

70 Literature search

71 The LSR follows the Preferred Reporting Items for Systematic Review and Meta-Analysis
72 (PRISMA) guideline (**supplement material 1, part 1**), and was registered in the *Prospective*
73 *Register of Systematic Reviews* (PROSPERO registration ID: CRD42020208935; updated on:
74 09 March 2022). All amendments since initial registration are available online. The methods
75 have been previously described in detail (2). In brief, we included studies of any design that
76 had a comparison group and investigated vaccine effectiveness (VE) against SARS-CoV-2
77 infection of any severity of COVID-19 vaccines approved by the European Medicine Agency
78 (EMA) in people ≥ 12 years of age (see **supplement material 1, part 2** for complete PICO
79 question). For this 3rd update of the LSR, we only considered studies that reported on outcomes
80 that are due to the SARS-CoV-2 Omicron variant or that occurred during a dominant circulation
81 of the Omicron variant. There were no restrictions with regard to publication language or status.

82 We searched the COVID-19 literature database constructed by the RKI library (see (2) and
83 **supplement material 1, part 3** for description of the database and the search strategy) for
84 studies published between 23 October 2021 and 14 January 2022. We added literature identified
85 by hand-search of websites and metasearch engines indicated in **supplement material 1, part**
86 **3** up to 11 February 2022. Potentially relevant publications were screened at title/abstract and
87 full-text level by pairs of independent investigators (AP, SK, MB, LSD, VP and/or WKS). Data
88 from included studies (see PROSPERO registration for details) was extracted in duplicate and
89 summarized in tables (AP, MB, VP, WKS). We considered VE data on the following three
90 comparisons by vaccine type (mRNA-based, vector-based, heterologous scheme, any vaccine):
91 1. completed primary immunization vs. no vaccination (i.e., placebo, no vaccination, or vaccine
92 not directed against COVID-19), 2. booster immunization vs. no vaccination, 3. booster
93 immunization vs. primary immunization. Outcomes of interest were VE against polymerase
94 chain reaction- (PCR) or antigen-test confirmed SARS-CoV-2 infection of “any type” (i.e.
95 studies did not indicate underlying symptoms), “symptomatic COVID-19”, and “severe

96 COVID-19” (including hospitalization, ICU-admission, or death due to SARS-CoV-2
97 infection). To investigate VE at different time points since vaccination, data was stratified into
98 four time periods (≈ 14 days, > 14 days up to 3 months, > 3 months up to 6 months, > 6 months).
99 As there was substantial heterogeneity across studies, we abstained from conducting a meta-
100 analysis, but summarized the studies as follows: We assessed the range of VE of any, mRNA-
101 or vector-based vaccines or for heterologous schedules against the outcomes described for the
102 different time strata by including VE estimates from all studies that provide VE estimates for
103 the respective time point (**supplement material, part 4**). If studies reported VE data for more
104 granular time points within the defined time stratum, it was always the estimate of the latest
105 time point within the stratum that contributed to the indicated range (e.g. if studies reported VE
106 after 2-4 and 5-9 weeks after vaccination, the estimate of 5-9 weeks was included in the depicted
107 effect range). Only for the time stratum “ ≈ 14 days”, VE estimates closest to 14 days were
108 included. The latter stratum included furthermore VE data that was only assessed at “ ≥ 14 days”
109 after primary vaccination, “ ≥ 7 days” post booster vaccination or when the time point of
110 assessment after primary immunization was not reported at all. To visualize VE over time after
111 primary and booster vaccination the estimates contributing to the VE range for the respective
112 time category were included in forest plots. Additionally, we assessed the percentage difference
113 of VE over time in studies reporting VE estimates for at least two different time points. We
114 provide the range of observed minimal and maximal differences across studies. For detailed
115 information we refer to the table of all extracted information provided in Appendix 2. ROBINS-
116 I was used to assess risk of bias (3). The certainty of the evidence included in the LSR was rated
117 using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)
118 approach (4, 5).

119

120 **3 Results**

121 **Study screening**

122 We identified a total of 8,428 entries in the database until 14 January 2022. Another 38
123 potentially relevant studies were added by hand-search until 11 February 2022. After
124 title/abstract and full-text screening, data from 26 studies (6-31) were extracted (**supplement**
125 **material 1, part 4; figure 1**). If studies referred to previously published references for further
126 information, these references were considered and information extracted if necessary. For pre-
127 print studies with several versions available, the most recent update published until 11 February
128 2022 was included.

129 **Characteristics of included studies**

130 The included studies, of which most (21/26) were not yet peer-reviewed, reported VE estimates
131 against infections (and related outcomes) with only the Omicron variant (5/26) or included VE
132 data against infections with the Delta variant for comparison (21/26). Fourteen studies assessed
133 VE using a test-negative design, eight based on a cohort design, three on a case-control design
134 and one study reported infection rates per vaccination status within a transmission study.

135 In the studies the SARS-CoV-2 variant causing the investigated outcome was identified either
136 from time periods with known dominant circulation of the Omicron (resp. Delta) variant in the
137 corresponding study location, from whole-genome sequencing (WGS), or through S-gene target
138 failure (SGTF) in PCR assays. Studies using the latter method subdivided the SARS-CoV-2
139 positive samples by the detection or non-detection of the S-gene in a three gene PCR assay. As
140 the SGTF is characteristic for the Omicron variant, but rare in the Delta variant, studies used

141 the detection of the S-gene as a proxy for the Delta variant, and the “non-detection” as a proxy
142 for the Omicron variant. As most studies report overall VE estimates without further
143 differentiating between WGS- or SGTF-variant assessment the data was synthesized only into
144 “dominance” and “sequencing/SGTF”.

145 Studies were conducted in ten different countries and mainly used national electronic registries
146 or claims data from the general population for laboratory, immunization and patient
147 characteristics. Only three studies investigated VE for specific populations such as in health
148 care workers, veterans or patients under hemodialysis therapy. Minimum age of included study
149 participants was 12 years (if reported). However, none of the studies provided subgroup data
150 for children or adolescents.

151 Twenty-two studies reported VE estimates for full primary immunization (as defined per study),
152 23 for a booster dose (additional dose after full primary immunization). One of the latter studies
153 compared the effect of a second booster dose (fourth doses) with a single booster dose. VE-
154 estimates for several time points after full primary immunization have been reported by eleven
155 studies, eight studies reported VE data for several time points after booster immunization.

156 Most studies investigated VE of mRNA-based vaccines (13 on Comirnaty, nine on Spikevax),
157 seven studies reported VE for vector-based vaccines (four on Vaxzevria, three on COVID-19
158 vaccines from Janssen) and seven studies did not differentiate VE per vaccine. None of the
159 studies provided data for Nuvaxovid.

160 **Prevention of infection with SARS-CoV-2 Omicron variant (without differentiation** 161 **between asymptomatic or symptomatic cases)**

162 Twelve studies (including between 1,220 and 2.2 million participants) reported the
163 effectiveness of COVID-19 vaccines in preventing infection of any type with SARS-CoV-2
164 Omicron variant (without differentiation between asymptomatic or symptomatic cases). After
165 full primary immunization VE across all studies ranged between 0 and 62% at “≈14 days” post
166 vaccination, compared to no vaccination. For the time-periods “>14 days up to 3 months”, “>3
167 months up to 6 months” and “>6 months” after vaccination VE-ranges, assessed across all
168 reported VE estimates, were 4.2 to 42.8%, 0 to 23% and 0 to 8.6%, respectively (**table 1, figure**
169 **2**). The data from the two studies reporting VE for at least two time points show a decline of
170 VE between >14 days to up to 6 months by 16 to 34% after vaccination with mRNA-based
171 vaccines (**figure 2**) (7, 14). As there was no VE data over time identified for vector-based
172 vaccines, unspecified vaccine or heterologous schedules respective VE decline could not be
173 assessed.

174 After booster vaccination, VE estimates at “≈14 days” post vaccination across all studies ranged
175 between 34 and 76%, compared to no vaccination, and between 14 and 53%, compared to full
176 primary immunization (12, 21). Follow-up data were insufficient to evaluate waning of
177 immunity after booster vaccination.

178 The study investigating VE of four vs. three doses of mRNA-based vaccines reported VE
179 estimate of 47% (95% CI 44-47) against Omicron infection at 12 or more days after the fourth
180 dose (29). VE ranges against infection with the Delta variant for the different time points are
181 provided in **supplement material 1, part 5**.

182 Risk of bias was serious to critical for all assessed studies (see **figure 3**). Key concern was no
183 or insufficient adjustment for confounders.

184 **Prevention of symptomatic COVID-19**

185 Seven studies, including between 430 and 2.2 million participants, estimated the effectiveness
186 of COVID-19 vaccines in preventing symptomatic infection with the SARS-CoV-2 Omicron
187 variant (**supplement material 1, part 4**). Compared to unvaccinated individuals, VE at ≈ 14
188 days after vaccination summarized from all studies reporting on this time point ranged between
189 6 and 76%. For the time-period “ >14 days up to 3 months”, “ >3 months up to 6 months” and
190 “ >6 months” VE ranges were 12-54%, 6.1-20.8%, and 0-13%, respectively. VE estimates from
191 studies that report data for at least two time points suggest a decrease in protective immunity
192 against symptomatic COVID-19 between 45-63% for mRNA-based vaccine recipients, and of
193 50% for vector-based vaccine recipients over the time period >14 days up to >6 months after
194 vaccination (**figure 4**, (8, 25)).

195 After booster vaccination, VE against symptomatic infection ranged between 19 and 73.9% at
196 “ ≈ 14 days” post vaccination, compared to no vaccination, and between 50 to 68%, compared
197 to primary vaccination (6, 9). For the time point “ >14 days up to 3 months” estimates were only
198 reported for the comparison with no vaccination and ranged between 43.7 and 65.4%. No study
199 reported VE for later observation periods. The two studies that provide data for both these time
200 periods show a 9-28% decrease in VE after booster vaccination with a mRNA-based vaccine
201 and between 32-34% after heterologous vaccination schemes (**figure 4** (8, 25)). However, 95%
202 confidence intervals between observation periods were partially overlapping.

203 Risk of bias was serious to critical for all but one of the assessed studies (see **figure 5**). The
204 remaining study was rated to have a moderate risk. All factors considered relevant for
205 confounding were taken into account, however residual confounding could not be ruled out.

206 **Prevention of severe COVID-19 (hospitalization, ICU-admission, or death)**

207 VE against severe COVID-19 was assessed in seventeen studies including 1,220 to 2.2 million
208 participants (**supplement material 1, part 4**). VE estimates in primary vaccinated compared
209 to unvaccinated individuals ranged from 3 to 84% at “ ≈ 14 days” post vaccination, between 21
210 and 95% at “ >14 days up to 3 months”, between 0 and 91% at “ >3 months up to 6 months” and
211 between 32.7 and 86% at “ >6 months” after vaccination. Studies reporting VE for at least two
212 time points indicate a decline by up to 40% for mRNA-based vaccines, and 15-67% for vector-
213 based vaccines between 14 days and ≥ 6 months after vaccination (see **figure 6**) (8, 20).
214 However, 95% confidence intervals were wide and overlapping across time points. One study
215 reported no difference in the first and last time point estimate (17), and another study reported
216 a small non-significant increase (VE at 30-180 days: 73.7% (95% CI 46.8-87); VE at ≥ 210
217 days: 80.7% (95% CI 71.3-87); (25)) (**supplement material 2**).

218 For booster vaccinated compared to unvaccinated individuals VE ranged from 12 to 100% at
219 “ ≈ 14 days” post vaccination and between 78 and 93.7% at “ >14 days up to 3 months”.
220 According to three studies, VE after booster vaccination remained stable over this time period
221 (17, 20, 25), irrespective of the vaccine or scheme used (mRNA-, vector-based or heterologous
222 vaccination). Only one study showed a decline of VE of approximately 12% over the respective
223 time period after mRNA-based vaccination (8). VE data was not available for later time periods.

224 For the comparison against full primary immunization we calculated VE of booster vaccination
225 against severe disease based on data from one study (6) that only reported data for 7 days after
226 booster vaccination (VE: 100% (95% CI 71.4-100)).

227 The study assessing the effect of a fourth vs. a third mRNA-based vaccine dose reported VE
228 against severe disease of 75% (95% CI 57-86) at ≥ 12 days after additional booster vaccination
229 (29). Data to assess duration of protection was not available.

230 In all but one studies risk of bias was serious to critical (see **figure 7**). The remaining study was
231 rated to have a moderate risk due to the potential for residual confounding.

232 **Effectiveness against the Omicron variant, compared to the Delta variant**

233 Twenty-one studies reported VE estimates both against infections with the Omicron and with
234 the Delta variant (**supplement material 1, part 4; supplement material 1, part 5;**
235 **supplement material 2**).

236 In addition to our PICO question, we included eight studies that estimated risk reduction of
237 infections with the Omicron variant compared to those with the Delta variant. Risk ratios from
238 these studies suggest that the risk for any type of SARS-CoV-2 infection and symptomatic
239 COVID-19 despite vaccination is higher for the Omicron variant than for the Delta variant.
240 Instead, risk of severe disease is lower in vaccinated people infected with the Omicron variant
241 compared to those vaccinated and infected with the Delta variant (**supplement material 1, part**
242 **6 and 7**).

243 **Publication bias**

244 Potential publication bias could not be explored through statistical testing and generating funnel
245 plots, as none of the comparisons/outcomes/time points involved sufficient studies.

246 **GRADE**

247 Overall, GRADE-certainty of evidence is very low for all outcomes, due to the underlying study
248 limitations and serious heterogeneity.

249

250 **4 Discussion**

251 This 3rd update of our LSR provides evidence on VE and duration of protection of EU-approved
252 COVID-19 vaccines against any type of infection, symptomatic infection, and COVID-19
253 associated severe disease (i.e. hospitalization, ICU admission, or death) caused by the SARS-
254 CoV-2 Omicron variant.

255 Though evidence is uncertain about the exact level of protection against all investigated
256 outcomes, both after primary and after a booster vaccination, data suggest that VE was higher
257 after booster when compared to primary immunization. Results suggest a rapid decline of
258 vaccine-induced protection after completion of the primary vaccination series. The effect is
259 profound for infections of any type, but less pronounced for severe disease. This is in line with
260 the findings of a recently published meta-regression analysis on pre-Omicron variants (32). VE
261 could be restored to high levels of protection by the booster dose, though first follow-up data
262 do also suggest a waning effect (8, 19, 25). However, VE against severe disease caused by
263 Omicron remained high for at least 3 months post booster immunization (no data for longer
264 follow-up available). Compared to VE against the Delta variant, vaccines were less effective
265 for all reported outcomes.

266 In the light of the more transmissible Omicron variant and the advancing immunization
267 campaigns across countries, evidence on the need and the timing of booster vaccination is of
268 increasing public health interest. Thus, we decided to adapt our PICO questions and inclusion
269 criteria and considered also studies that compare booster vaccinated individuals with primary
270 vaccinated ones. The effect of waning immunity was assessed through stratifying VE data into
271 multiple observation periods.

272 As included studies were highly heterogenous (e.g. in terms of analyzed time point after
273 vaccination, study population, applied vaccine schedules, if reported at all) and had serious to
274 critical risk of bias, we decided not to perform meta-analyses, but provide ranges of reported
275 VE estimates across studies to increase transparency and prevent misinterpretation. As studies
276 assessed VE inconsistently for different time points or periods, a standardized assessment for
277 time points of VE evaluation, as suggested by WHO (33), would facilitate the comparison of
278 evidence across studies and better allow a synthesis of the evidence.

279 Most studies included here used the test-negative design. This study design was initially
280 introduced to estimate VE against seasonal influenza, and thought to control for differences in
281 seeking medical care (34). In the COVID-19 era, the test-negative studies might be prone to
282 bias caused by specific testing strategies or behaviors at the study location. However, those are
283 mainly not reported in the studies, making it difficult to interpret reported estimates, when
284 individuals are not tested due to underlying symptoms. Most studies did not indicate the
285 vaccination schedule applied for full primary immunization or the booster dose. For
286 immunocompromised people a three-dose primary vaccination schedule is recommended by
287 the WHO Strategic Advisory Group of Experts on Immunization to improve immune response.
288 As this recommendation is implemented in many countries¹, it is possible that VE estimates for
289 a booster schedule include those that received a 3rd doses within an “optimized” schedule for
290 immunocompromised people.

291

292 This 3rd update provides a comprehensive overview of the currently available evidence on VE
293 against infection with the SARS-CoV-2 Omicron variant. We provide an in-depth analysis of
294 the VE estimates extracted from the included studies that were identified following a pre-
295 registered protocol. We conducted thorough risk of bias assessment of the studies, and
296 evaluated the certainty of evidence using the GRADE approach.

297 Due to the highly dynamic publication landscape in this field, additional studies have been
298 published since our last search that are not captured by this analysis. In fact, we are aware of at
299 least two studies reporting on adolescents, which were published after our data cut (35, 36). As
300 in adults, lower VE against infections and severe disease were observed for the Omicron
301 variant, when compared to the Delta variant. However, data on duration of protection are
302 contradicting. While one study reported a decrease in VE against hospitalizations by 6-19% at
303 more than 5 months after primary immunization (35). The second study did not identify a
304 decrease in VE against any infections but was based only on few events (36). In addition to
305 studies not included as they were published after our final search date, we noticed that some
306 studies updated data on preprint servers after initial publication including data on longer follow-
307 up periods. We therefore cannot exclude that authors revised the available pre-print versions
308 including additional data after we completed data extraction for this update. Further, we cannot
309 exclude a risk of potential bias as real-life observation are based on retrospective analyses which
310 are not systematically registered. Thus, intent and possibility of publication might depend on
311 observed results. However, due to the increase of publications on pre-print servers, the risk of
312 publication bias is probably low.

313 Additional data limitations stem from the fact that VE estimates for more than one vaccine were
314 reported.

315

¹ An additional dose is recommended for immunocompromised people in all eight countries where included studies that reported VE estimates on booster immunization were conducted (Canada, Denmark, Netherlands, Norway, Qatar, South Africa, United Kingdom, United States of America).

316 **5 Conclusion**

317 Current evidence suggests that the effectiveness of COVID-19 vaccines licensed in the EU is
318 low after primary vaccination, and improved after booster vaccination in preventing infections
319 with the SARS-CoV-2 Omicron variant. For both primary and booster immunization it is
320 characterized by a rapid decrease over time. VE against severe courses of COVID-19 remains
321 generally high.

322 Studies included in this update were very heterogenous, therefore, pooling of estimates was not
323 appropriate. To allow statistical synthesizes of effects, studies need to be comparable for
324 clinical and meta-epidemiological aspects. Thus, certain standards for VE studies, as suggested
325 by WHO, are useful to better inform vaccination guidelines and reliably assess the public health
326 impact of vaccination campaigns.

327

328 **6 Conflict of Interest**

329 *The authors declare that the research was conducted in the absence of any commercial or*
330 *financial relationships that could be construed as a potential conflict of interest.*

331

332 **7 Author Contributions**

333 WKS was first and second reviewer, responsible for data extraction, performed bias assessment
334 and drafted the manuscript. VP was first and second reviewer, responsible for data extraction,
335 performed bias assessment, conducted GRADE assessment and contributed to the manuscript.

336 AP was first and second reviewer, responsible for data extraction, performed bias assessment
337 and contributed to the manuscript. MB was first reviewer, responsible for data extraction,
338 performed bias assessment and contributed to the manuscript. MW, SK, LSD and BG were first
339 reviewers and contributed to the manuscript. MT provided input into the interpretation of the
340 results and developed forest plots. SVB and JK contributed to the manuscript. OW held general
341 oversight of the conducted work and revised the manuscript. TH conceived the study and
342 contributed to the manuscript. All authors contributed to the interpretation of the data and
343 provided important intellectual content to the manuscript.

344

345 **8 Funding**

346 None.

347

348 **9 Acknowledgements**

349 We sincerely thank the authors of Andrews et al. and Kahn et al. for providing us with
350 additional data.

351 References

- 352 1. World Health Organization. Weekly epidemiological update on COVID-19 - 22
353 March 2022 [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-march-20222022)
354 [covid-19---22-march-20222022](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-march-20222022) [
- 355 2. Harder T, Koch J, Vygen-Bonnet S, Kulper-Schiek W, Pilic A, Reda S, et al. Efficacy
356 and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a
357 living systematic review, 1 January to 14 May 2021. *Euro Surveill.* 2021;26(28).
- 358 3. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al.
359 ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ.*
360 2016;355:i4919.
- 361 4. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines:
362 1. Introduction-GRADE evidence profiles and summary of findings tables. *Journal of clinical*
363 *epidemiology.* 2011;64(4):383-94.
- 364 5. Schünemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, et al.
365 GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in
366 nonrandomized studies should be used to rate the certainty of a body of evidence. *Journal of*
367 *clinical epidemiology.* 2019;111:105-14.
- 368 6. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Tang P, Hasan MR, et al.
369 Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2
370 Omicron (B.1.1.529) infection in Qatar. *medRxiv.* 2022.
- 371 7. Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg H-D, Krause TG, Mølbak K, et
372 al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants
373 following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish
374 cohort study. *medRxiv.* 2021.
- 375 8. UK Health Security Agency. COVID-19 vaccine surveillance report – week 4
376 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf2022)
377 [file/1050721/Vaccine-surveillance-report-week-4.pdf2022](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf2022) [updated January 27, 2022.
- 378 9. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al.
379 Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection
380 Caused by the SARS-CoV-2 Omicron and Delta Variants. *JAMA.* 2022;327(7):639-51.
- 381 10. Young-Xu Y. Effectiveness of mRNA COVID-19 Vaccines against Omicron among
382 Veterans. *medRxiv.* 2022.
- 383 11. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al.
384 Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and
385 severe outcomes. *medRxiv.* 2022.
- 386 12. Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Møller CH, Skov RL, et
387 al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. *medRxiv.* 2021.
- 388 13. Sheikh A, Kerr S, Woolhouse M, McMenemy J, Robertson C. Severity of Omicron
389 variant of concern and vaccine effectiveness against symptomatic disease: national cohort
390 with nested test negative design study in Scotland
391 [https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-](https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness-:)
392 [vaccine-effectiveness-:](https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness-:) Edinburgh Research Explorer; 2021 [updated December 22, 2021.
- 393 14. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of
394 mRNA-1273 against SARS-CoV-2 omicron and delta variants. *medRxiv.* 2022.
- 395 15. Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al.
396 Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency
397 Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods
398 of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-
399 January 2022. *MMWR Morbidity and mortality weekly report.* 2022;71(4):139-45.

- 400 16. Willett BJ, Grove J, MacLean OA, Wilkie C, Logan N, Lorenzo GD, et al. The hyper-
401 transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine
402 escape and a switch in cell entry mechanism. medRxiv. 2022.
- 403 17. Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, et al. BNT162b2
404 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and
405 Emergency Department Admission in a Large US Health System: A Test-Negative Design.
406 2022.
- 407 18. Jalali N, Brustad HK, Frigessi A, MacDonald E, Meijerink H, Feruglio S, et al.
408 Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant
409 compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data.
410 medRxiv. 2022.
- 411 19. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al.
412 Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-
413 CoV-2 Variants in the United States: A Prospective Observational Study. medRxiv. 2022.
- 414 20. Nyberg T, Ferguson N, Nash S, Webster H, Flaxman S, Andrews N, et al.
415 Comparative Analysis of the Risks of Hospitalisation and Death Associated with SARS-CoV-
416 2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England. SSRN. 2022.
- 417 21. Andeweg SP, de Gier B, Eggink D, van den Ende C, van Maarseveen N, Ali L, et al.
418 Protection of COVID-19 vaccination and previous infection against Omicron BA.1 and Delta
419 SARS-CoV-2 infections, the Netherlands, 22 November 2021- 19 January 2022. medRxiv.
420 2022.
- 421 22. Gray GE, Collie S, Garrett N, Goga A, Champion J, Zylstra M, et al. Vaccine
422 effectiveness against hospital admission in South African health care workers who received a
423 homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results
424 of the Sisonke 2 Study. medRxiv. 2021.
- 425 23. Veneti L, Bøås H, Bråthen Kristoffersen A, Stålcrantz J, Bragstad K, Hungnes O, et al.
426 Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-
427 CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to
428 January 2022. Eurosurveillance. 2022;27(4):2200077.
- 429 24. Spensley K, Gleeson S, Martin P, Thomson T, Clarke CL, Pickard G, et al.
430 Comparison of vaccine effectiveness against the Omicron (B.1.1.529) variant in patients
431 receiving haemodialysis. medRxiv. 2022.
- 432 25. Chemaitelly H, Ayoub HH, AlMukdad S, Tang P, Hasan MR, Yassine HM, et al.
433 Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against
434 symptomatic SARS-CoV-2 Omicron infection in Qatar. medRxiv. 2022.
- 435 26. Nunes MC, Sibanda S, Baillie VL, Kwatra G, Aguas R, Madhi SA, et al. SARS-CoV-
436 2 Omicron symptomatic infections in previously infected or vaccinated South African
437 healthcare workers. medRxiv. 2022.
- 438 27. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2
439 Vaccine against Omicron Variant in South Africa. New England Journal of Medicine.
440 2021;386(5):494-6.
- 441 28. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes
442 among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern
443 California. medRxiv. 2022.
- 444 29. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al.
445 Protection by 4th dose of BNT162b2 against Omicron in Israel. medRxiv. 2022.
- 446 30. Davies M-A, Kassanje R, Rosseau P, Morden E, Johnson L, Solomon W, et al.
447 Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave
448 compared with previous waves in the Western Cape Province, South Africa. medRxiv. 2022.
- 449 31. Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et
450 al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination

- 451 status, sex, age and comorbidities – surveillance results from southern Sweden. medRxiv.
452 2022.
- 453 32. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al.
454 Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease:
455 results of a systematic review and meta-regression. *The Lancet*. 2022.
- 456 33. World Health Organization. Evaluation of COVID-19 vaccine effectiveness - Interim
457 guidance [https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.12021)
458 [measurement-2021.12021](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.12021) [updated March 17, 2021].
- 459 34. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine
460 effectiveness. *Vaccine*. 2013;31(17):2165-8.
- 461 35. Klein NP, Stockwell MS, Demarco M, Gaglani M, Kharbanda AB, Irving SA, et al.
462 Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing
463 COVID-19-Associated Emergency Department and Urgent Care Encounters and
464 Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17
465 Years - VISION Network, 10 States, April 2021-January 2022. *MMWR Morbidity and*
466 *mortality weekly report*. 2022;71(9):352-8.
- 467 36. Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of
468 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection
469 Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort,
470 July 2021-February 2022. *MMWR Morbidity and mortality weekly report*. 2022;71(11):422-
471 8.
- 472
- 473

474 Table 1: Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variant
 475 infection (infection (any type), symptomatic COVID-19, and severe COVID-19
 476 (hospitalization, ICU admission, or death))

	Vaccine(s) used for immunization	Range of adjusted vaccine effectiveness (95% CI) ^{a,b,c}			
		≈14 days ^d	>14 days up to 3 months	>3 months up to 6 months	>6 months
Infection (any type)					
Full primary immunization	mRNA-based (any) ^e	16% (0–37) to 55.2% (23.5–73.7); (7, 10, 14, 16, 18, 24)	4.2% (-30.8–29.8) to 42.8% (33.8–50.7); (7, 14, 16)	-76.5% (-95.3– -59.5) to 23% (15.8–29.6); (7, 14)	8.6% (3.3–13.6); (14)
	Vector-based (any) ^f	-4% (-97–43) to 11.4 (NR to NR); (16, 24)	11.4% (NR to NR); (16)
	Any vaccine ^h	-13% (-38–8) to 62% (58–66); (11, 12, 21)	..	-38% (-61– -18); (11)	-16% (-62–17); (11)
	Heterologous scheme ^g
Booster immunization	mRNA-based (any) ^e	34% (16–49) to 66% (36–81); (6, 10, 11, 14, 18, 24) ⁱ	54.6% (30.4–70.4) ⁱ ; (7)
	Vector-based (any) ^f
	Any vaccine ^h	38% (29–46) to 76% (72–79); (16, 21, 24) ⁱ
	Heterologous scheme ⁱ
Symptomatic COVID-19					
Full primary immunization	mRNA-based (any) ^e	41% (-57–77) to 76% (72–79); (8, 25, 26)	44.8% (16–63.8) to 54% (49–58); (8, 25)	13.3% (12.0–14.7) to 20.8% (13.7–27.4); (8, 25)	-9.4% (-16.3–2.8) to 13% (3–22); (8, 25)
	Vector-based (any) ^f	6% (-103–56) to 49.8% (40.7–57.5); (8, 26)	35.7% (27.7–42.8); (8)	6.1% (4.1–8.1); (8)	-1.0% (-2.4–0.3); (8)
	Any vaccine ^h	36% (24–45); (11) ^k	12% (3–21); (11) ^k	15% (8–22); (11) ^k	2% (-17–17); (11) ^k
	Heterologous scheme ^g
Booster immunization	mRNA-based (any) ^e	50.0% (41.2–57.4) to 73.9% (73.2–74.5); (6, 8, 9, 25) ⁱ	43.7% (32.9–52.7) to 65.4% (63.9–66.9); (8, 25)
	Vector-based (any) ^f	19% (-43–54); (26)
	Any vaccine ^h	61% (56–65); (11) ^k
	Heterologous scheme ⁱ	63.2% (62.6–63.8) to 70.7% (70.1–71.2);	54.0% (53.3–54.8) to 62.1% (61.1–63.1); (8)

Third interim analysis of a living systematic review

		(8)			
Severe COVID-19 (hospitalization, ICU admission, or death)					
Full primary immunization	mRNA-based (any) ^e	3% (-114–56) to 81% (65–90); (8, 14, 15, 17, 19, 20, 25, 27, 28)	44% (-14–72) to 95% (57–99); (8, 20)	57.3% (42.7–68.2) to 91% (31–99); (8, 20)	34.9% (17.7–48.4) to 80.7% (71.3–87); (8, 15, 17, 20, 25)
	Vector-based (any) ^f	17% (-246–80) to 84% (-16–98); (20, 28)	21% (-81–66) to 85% (54–95); (20, 22)	-8% (-213–62) to 55.8% (34.1–70.3); (8, 20)	32.7% (19.7–43.6); (8)
	Any vaccine ^h	55% (-106–90) to 77% (-91–97); (11, 23, 24)	37% (-71 – 77); (11)	75% (51–87); (11)	41 % (-22–72) to 86% (-12 – 98); (11, 23)
	Heterologous scheme ^g
Booster immunization	mRNA-based (any) ^e	12% (-45–46) to 100% (71.4–100); (6, 8, 11, 14, 15, 17, 19, 20, 25, 28) ⁱ	78% (76–80) to 93.7% (80.3–98); (8, 17, 20)
	Vector-based (any) ^f	78% (76–80) to 84% (67–92); (20, 22)	79% (76–81) to 84% (80–88); (20)
	Any vaccine ^h	60% (-163–90) to 956% (87–98); (11, 23, 24)
	Heterologous scheme ^j	86.9% (82.8–90.1) to 91.4% (86.8–94.4); (8)	85% (81.2–88) to 91.2% (82.8–95.5); (8)

477 **Footnotes:**

478 ^a If not indicated otherwise, vaccine effectiveness (VE) estimates refer to the comparison of vaccinated
 479 (2 or 3 doses, respectively) vs. unvaccinated;

480 ^b Provided VE estimates refer to the last reported time point per observation period (e.g. if studies
 481 reported VE after 2-4 and 5-9 weeks, the estimate of 5-9 weeks was included in the depicted effect
 482 range)

483 ^c Several effect ranges are derived from single studies providing data for different vaccine types

484 ^d time point closest to 14 days

485 ^e Comirnaty or Spikevax

486 ^f Vaxzevria or COVID-19-vaccine Janssen

487 ^g 1st dose with vector-based vaccine followed by prime booster dose of mRNA-based vaccine

488 ^h Studies include recipients of different vaccine types, and data was not further stratified

489 ⁱ Includes at least one study comparing booster vs. primary vaccination schedules (i.e., 3 vs. 2 doses)


490 ^j 1st dose with vector-based vaccine followed by prime booster dose, and 3rd dose of mRNA-based
 491 vaccine OR vector-based primary vaccination followed by one booster dose of mRNA-based vaccine

492 ^k One study estimated VE against vaccinated individuals who received second dose before ≥ 25 weeks,
 493 because of insufficient unvaccinated individuals available for analysis (13). VE against symptomatic
 494 infection with Omicron and Delta was estimated for 16-49 and 50+ year old's, respectively. Estimates
 495 are provided for all reported observation periods in supplement material 2

496

497

498 Figure 1. PRISMA flow chart




499

500

Third interim analysis of a living systematic review

501 Figure 2. Forest plots of VE estimates against any type of SARS-CoV-2 infection of the
 502 Omicron variant after full primary immunization and booster dose, as reported in the study for
 503 the defined time strata after immunization. For booster immunization the COVID-19 vaccine
 504 used for primary immunization is indicated.



Notes: Full primary immunization with any vaccine (a), any mRNA-based vaccine (am), Comirnaty (c), or Vaxzevria (v);
 *unadjusted estimates, calculated by the authors from data provided in the study; ¹ VE overall; ² VE in people previously infected with SARS-CoV-2; ³ VE estimates in people receiving the first dose of COVID-19 vaccine before SARS-CoV-2 infection was reported as 62% (CI 95%: 58-66); ⁴ VE in people not previously infected with SARS-CoV-2


505
 506 Figure 3. Risk of Bias assessment for SARS-CoV-2 infection (any type) of the Omicron variant



507
 16


Third interim analysis of a living systematic review

508 Figure 4. Forest plots of VE estimates against symptomatic COVID-19 due to SARS-CoV-2
 509 infection of the Omicron variant after full primary immunization and booster dose, as reported
 510 in the study for the defined time strata after immunization. For booster immunization the
 511 COVID-19 vaccine used for primary immunization is indicated.



512

513 Figure 5. Risk of Bias assessment for symptomatic COVID-19 due to SARS-CoV-2 infection
 514 of the Omicron variant




515

516

Third interim analysis of a living systematic review


517 Figure 6. Forest plots of VE estimates against severe COVID-19 (incl. hospitalization, ICU
 518 admission or death) due to SARS-CoV-2 infection of the Omicron variant after full primary
 519 immunization and booster dose, as reported in the study for the defined time strata after
 520 immunization. For booster immunization the COVID-19 vaccine used for primary
 521 immunization is indicated.



522

523

524 Figure 7. Risk of Bias assessment for severe COVID-19 (incl. hospitalization, ICU admission
 525 or death) due to SARS-CoV-2 infection of the Omicron variant



526